B. Riley Comments on TG Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at B. Riley upped their Q3 2024 earnings per share estimates for shares of TG Therapeutics in a research report issued on Monday, July 8th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, up from their previous estimate of ($0.02). The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.01) per share. B. Riley also issued estimates for TG Therapeutics’ FY2024 earnings at ($0.09) EPS.

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. LADENBURG THALM/SH SH boosted their price objective on TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Finally, HC Wainwright boosted their price objective on TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.83.

TG Therapeutics Stock Up 4.3 %

Shares of TG Therapeutics stock opened at $21.39 on Wednesday. The business’s fifty day moving average price is $17.36 and its two-hundred day moving average price is $16.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. The company has a market capitalization of $3.31 billion, a P/E ratio of 93.00 and a beta of 2.23. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $25.82.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm’s revenue was up 713.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) EPS.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently modified their holdings of the stock. Pingora Partners LLC bought a new stake in TG Therapeutics during the 4th quarter worth approximately $27,000. DekaBank Deutsche Girozentrale acquired a new position in TG Therapeutics during the 1st quarter worth $58,000. Anchor Investment Management LLC acquired a new position in TG Therapeutics during the 4th quarter worth $80,000. Lazard Asset Management LLC acquired a new position in TG Therapeutics during the 1st quarter worth $91,000. Finally, NBC Securities Inc. lifted its holdings in TG Therapeutics by 34.5% during the 4th quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,409 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.